1. Preface 2
1.1 Table of Contents 3
1.2 Abbreviations 5
1.3 Related Reports 11
1.4 Upcoming Related Reports 12

2. Executive Summary 13
2.1 Key Findings 14
2.2 KOL and Payer Insights on Market Access, Pricing and Reimbursement in Oncology in the 5EU 15

3. Overview of Market Access, Pricing and Reimbursement 16
3.1 Cancer in Europe 18
3.2 What is Market Access? 19
3.3 Marketing Authorization 20
3.4 Marketing Authorization for Early Patient Access 21
3.5 Cancer Medicines Approved Through EMA Access Schemes 22
3.6 Health Technology Assessments (HTAs) 23
3.7 Clinical Endpoints in Oncology 24
3.8 Scientific and Value Assessment of Oncology Medicines in HTAs 25
3.9 Patient Reported Outcomes in HTAs 27
3.10 EU Pricing and Reimbursement - Overview 28
3.11 EU Pricing and Reimbursement - Pricing Models 29
3.12 EU Pricing and Reimbursement - Agreements 30
3.13 Valuing New Medicines 31
3.14 EU Pricing and Reimbursement - Cost-containment measures 32
3.15 Cost-containment Measures of Oncology Medicines in the Healthcare System 33
3.16 The Role of the Payer in Market Access 34

4. Market Access, Pricing and Reimbursement in the 5EU 37
4.1 Demographic and Socio-economic Factors in Healthcare in the 5EU 39
4.2 Healthcare Systems of the 5EU 40
4.3 Health-Related Statistics in the 5EU 41
4.4 France 43
4.5 Germany 57
4.6 Italy 68
4.7 Spain 82
4.8 UK 92
4.9 Summary 108

5. Market access of new and innovative oncology therapies in the 5EU and related case studies 113
5.1 Overview of Oncology Medicines 115
5.2 Immuno-oncology Therapies 121
5.3 Biosimilars 131

6. Current and Future Outlook 139
6.1 Unmet Needs and Current Issues in Oncology 141
6.2 Market Trends in Oncology 145
6.3 Market Changes in Oncology Over the Next 5-10 years 146
6.4 Drivers and Barriers in Oncology Drug Development and Market Access 148
6.5 The Issue of High Prices and Uncertain Value of Oncology Drugs 150
6.6 Pipeline Pre-Registration Oncology Drugs in Europe 151

7. Appendix 155
7.1 ResearchMethodology 156
7.2 Primary Research 157
7.3 About the Authors 158
7.4 About GlobalData 160
7.5 Contact Us 161
7.6 Disclaimer 162

Companies Mentioned
- Alliance
- Amgen
- Aop Orphan Pharmaceuticals
- Ariad Pharmaceuticals
- Array BioPharma
- AstraZeneca
- Astellas
- Biocon
- Biogaran
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celgene
- Celltrion
- CTI BioPharma
- Dendreon
- Difa Cooper
- Eisai
- Eli Lilly
- Erytech Pharma
- Genzyme
- Gilead
- Helsinn Birex
- Industrial Farmaceutica Cantabria
- Ipsen
- Janssen-Cilag
- Jazz Pharmaceuticals
- Johnson & Johnson
- Kedrion
- Kern Pharma
- Kite
- Kyowa Kirin
- Laboratorios Inibsa
- Mabion
- Meda
- Medac
- MedImmune
- MolMed
- MSD
- Mundipharma
- Mylan
- Napp Pharmaceuticals
- Nektar Therapeutics
- Northwest Biotherapeutics
- Novartis
- Oasmia Pharmaceutical
- Ono Pharmaceutical
- Orphelia Pharma
- Pharma Mar
- Pierre Fabre M├ędicament
- Pfizer
- Puma Biotechnology
- Regeneron
- Roche
- Sandoz
- Sanofi
- Sunesis Europe
- Takeda
- XBiotech